FDA Approves Furoscix for Pediatric Patients: What This Means for Heart and Kidney Care at Home
The U.S. Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include pediatric patients weighing 43 kilograms (about 95 pounds) or more, marking a significant milestone in the treatment of fluid overload associated with chronic heart failure (CHF) and chronic kidney disease (CKD). This decision opens the door to more flexible, at-home treatment options for a carefully defined pediatric population and reinforces the growing role of drug-device combinations in modern care delivery.
Announced by MannKind Corporation in December 2025, the approval reflects not only progress in pediatric access to advanced therapies but also broader innovation in how diuretic treatments may be delivered outside hospital settings.
This article breaks down what Furoscix is, why this FDA approval matters, how it impacts pediatric and adult care, and what lies ahead with the investigational Furoscix ReadyFlow™ Autoinjector.
What Is Furoscix?
Furoscix is a subcutaneous formulation of furosemide, a loop diuretic that has been used for decades to manage edema (fluid overload) in patients with heart failure and kidney disease. Unlike traditional oral or intravenous (IV) furosemide, Furoscix is delivered via an On-body Infusor, allowing patients to receive IV-equivalent diuretic therapy outside of a hospital or infusion center.
Key Indications
Furoscix is indicated for the treatment of edema related to:
- Chronic heart failure (CHF)
- Chronic kidney disease (CKD), including nephrotic syndrome
With the latest FDA approval, Furoscix is now indicated for:
- Adult patients
- Pediatric patients weighing ≥43 kg
FDA Approval for Pediatric Patients: Why It Matters
Addressing an Unmet Need
Pediatric patients with heart or kidney disease often face limited outpatient treatment options when fluid overload worsens. Hospital admissions for IV diuretics are common, disruptive, and costly—not only financially but emotionally for children and families.
By approving Furoscix for pediatric patients who meet the weight threshold, the FDA has enabled:
- Greater treatment flexibility
- Reduced need for hospital-based IV therapy
- Potential improvements in quality of life for patients and caregivers
This approval also fulfills post-marketing requirements under the Pediatric Research Equity Act (PREA), demonstrating regulatory confidence in the safety and effectiveness of the therapy for this specific population.
How the Furoscix On-Body Infusor Works
The Furoscix On-body Infusor is a wearable delivery system that administers furosemide subcutaneously over a controlled period. The device is designed for home use, with built-in alerts to notify patients if infusion is interrupted.
Benefits of the On-Body Infusor
- Delivers IV-equivalent diuretic dosing
- Avoids gastrointestinal absorption issues seen with oral diuretics
- Reduces emergency department visits
- Enables earlier intervention during fluid overload episodes
However, patients must be trained to monitor alarms and ensure proper device use, as movement or fluid contact can interrupt infusion.
Furoscix ReadyFlow™ Autoinjector: The Next Evolution
In addition to the pediatric approval, MannKind announced that the FDA has accepted for review a supplemental New Drug Application (sNDA) for the Furoscix ReadyFlow Autoinjector, an investigational device that could further transform diuretic therapy.
What Makes ReadyFlow Different?
If approved, ReadyFlow would:
- Deliver an 80 mg/mL subcutaneous injection
- Provide IV-equivalent dosing in under 10 seconds
- Eliminate lengthy infusion times
- Enable rapid, on-demand treatment at home
The FDA has assigned a PDUFA target action date of July 26, 2026.
Comparison: Furoscix Delivery Options
| Feature | On-Body Infusor | ReadyFlow Autoinjector* |
|---|---|---|
| Delivery Time | Several minutes | <10 seconds |
| FDA Approval Status | Approved (adults & pediatric ≥43 kg) | Under FDA review |
| Setting | At home | At home |
| Drug Strength | 80 mg/10 mL | 80 mg/mL |
| Ease of Use | Wearable device | Single injection |
| Potential Impact | Reduced hospital visits | Rapid intervention, greater convenience |
*ReadyFlow Autoinjector is investigational and not yet FDA-approved.
Intellectual Property and Long-Term Protection
MannKind also disclosed that the U.S. Patent and Trademark Office (USPTO) issued five new U.S. patents covering the Furoscix ReadyFlow Autoinjector. These patents protect:
- High-concentration liquid formulations of furosemide
- Associated methods of treatment
- Drug-device combination technology
If approved, these patents would be listed in the FDA’s Orange Book and could provide protection through 2040, strengthening MannKind’s competitive position in the heart failure and CKD markets.
Safety Considerations and Warnings
Like all loop diuretics, Furoscix carries important safety considerations.
Contraindications
Furoscix should not be used in patients with:
- Anuria
- Known hypersensitivity to furosemide, formulation components, or medical adhesives
Key Safety Risks
- Fluid and electrolyte imbalances
- Dehydration and hypotension
- Worsening renal function
- Ototoxicity (including tinnitus or hearing loss), especially with high doses or rapid administration
Monitoring Requirements
Patients receiving Furoscix should undergo regular monitoring of:
- Electrolytes
- Renal function (BUN, creatinine)
- Blood glucose and uric acid
The most common adverse reactions reported in clinical trials were injection-site and skin reactions, including redness, bruising, swelling, and pain.
Implications for Patients, Providers, and Health Systems
The expansion of Furoscix into pediatric care and the potential approval of ReadyFlow reflect a broader shift toward hospital-at-home models and patient-centric drug delivery.
Potential Benefits
- Reduced hospital admissions and ER visits
- Lower healthcare costs
- Improved patient autonomy
- Earlier intervention during worsening symptoms
For healthcare providers, these innovations may help optimize resource utilization while maintaining clinical effectiveness.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases. With deep expertise in drug-device combinations, the company aims to deliver therapies that integrate seamlessly into patients’ daily lives. Its portfolio spans diabetes, pulmonary hypertension, and fluid overload associated with heart and kidney disease.
Conclusion
The FDA’s approval of Furoscix for pediatric patients weighing 43 kg or more represents a meaningful step forward in expanding access to advanced diuretic therapy beyond traditional hospital settings. Combined with the ongoing review of the Furoscix ReadyFlow Autoinjector and strengthened patent protection, MannKind is positioning Furoscix as a cornerstone therapy in the evolving management of fluid overload.
As regulatory decisions unfold in 2026, Furoscix may continue to redefine how patients—both young and adult—manage chronic heart and kidney conditions from the comfort of home.
Sources
- MannKind Corporation Press Release, December 23, 2025
- U.S. Food and Drug Administration (FDA) Drug Approval Communications
Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding medical conditions, medications, or treatment decisions. Drug indications, warnings, and approvals are subject to change based on ongoing regulatory review.